WIRB-Copernicus Group Supports Accelerated Clinical Trial Agreement
The ACTA was initiated in 2012 by the National Center for Advancing Translational Sciences (NCATS) through its Clinical and Translational Science Awards program in collaboration with representatives from several pharmaceutical companies to facilitate negotiations between institutional research sites and industry sponsors.
WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for human research and software solutions, announced that it will encourage members of its Global Research Network (GRN) to accept the Accelerated Clinical Trial Agreement (ACTA) as their default agreement for industry-sponsored, multi-center clinical trials.
The ACTA was initiated in 2012 by the National Center for Advancing Translational Sciences (NCATS) through its Clinical and Translational Science Awards program in collaboration with representatives from several pharmaceutical companies to facilitate negotiations between institutional research sites and industry sponsors. The goal was to create a straightforward and unambiguous document which clearly sets forth the regulatory and contractual obligations of both parties, and presents language which – while perhaps not ideal for either party – is acceptable to both. Adoption and use of the ACTA would expedite the contract process and reduce the time it takes to start up clinical trials.
While the Accelerated Clinical Trial Agreement (ACTA) was initiated in 2012, it took two years to develop, and is just being introduced now. To date, approximately 225 institutions have agreed to the terms of the ACTA. WCG aims to increase that number significantly by promoting ACTA to the 1,200 institutions that belong to its GRN, which is a group comprised of research-intensive hospitals and universities, including one-third of all U.S. academic medical centers, 27 of which are CTSA institutions and have agreed to accept the ACTA without revision.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
